

11/07/01  
1042 U.S. PTO

Attorney Docket P1042C1  
PATENT

J1000 U.S. PTO  
10/005306  
11/07/01

CERTIFICATION UNDER 37 CFR 1.10

EL 599 583 175 US: Express Mail Number

November 7, 2001: Date of Deposit

I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

  
Aida Guiam

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION  
Assistant Commissioner of Patents  
Washington, D.C. 20231

**NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)**

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Robert A. Lazarus,  
Clark Q. Pan

Title: Human DNase I Hyperactive Variants

**1. Type of Application**

- This application is for an original, non-provisional application.  
 This is a non-provisional application claiming priority to provisional application no. \_\_ filed \_\_\_, the entire disclosure of which is hereby incorporated by reference.  
 This is a [ ] continuation-in-part [ x ] continuation [ ] divisional application claiming priority to application Serial Number 08/663,831, filed June 14, 1996, the entire disclosure of which is hereby incorporated by reference.

**2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b)  
(Non-provisional )**

- 19 pages of specification  
2 pages of claims  
1 page(s) of abstract  
4 sheet(s) of drawings  
[ ] formal [x] informal

**3. Declaration or Oath**

(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)

An executed declaration of the inventor(s) [] is enclosed [x] will follow.

(for Cont./Div. where inventorship is the same or inventor(s) being deleted)

A copy of the executed declaration/oath filed in the prior application is enclosed  
(37 CFR 1.63(d))

(for Cont./Div. where inventor(s) being deleted)

A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

**4. Assignment**

(for new and CIP applications)

An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [] will follow.

(for cont./div.)

The prior application is assigned of record to Genentech, Inc.

**5. Amendments (for continuation and divisional applications)**

Cancel in this application original claims 1-20 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

**Relate Back -- 35 U.S.C. 120 or 35 U.S.C. 119**

Amend the specification by inserting before the first line the sentence:

--This is a

non-provisional application

continuation

divisional

continuation-in-part

of co-pending application(s)

Serial No. 08/663,831 filed on June 14, 1996, which application is incorporated herein by reference and to which application priority is claimed under 35 USC §120. --

International Application    filed on    which designated the U.S., which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC

§120.--

provisional application No. filed ., the entire disclosure of which is hereby incorporated by reference and to which application(s) priority is claimed under 35 USC §119.--

**6. Fee Calculation (37 CFR 1.16)**

The fee has been calculated as follows:

<b>CLAIMS FOR FEE CALCULATION</b>					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$740.00
Total Claims	3	- 20 =	0	× \$18.00	\$0.00
Independent Claims	3	- 3 =	0	× \$80.00	\$0.00
Multiple dependent claim(s), if any				+ \$270.00	\$0.00
<b>Filing Fee Calculation</b>					<b>\$740.00</b>

**7. Method of Payment of Fees**

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$740.00. A duplicate copy of this transmittal is enclosed.

**8. Authorization to Charge Additional Fees**

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

**9. Additional Papers Enclosed**

- Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence
- A new Power of Attorney or authorization of agent.
- Other: Limited Recognition Under 37 CFR § 10.9(b)\*

**10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)**

[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]

- A petition, fee and/or response has been filed to extend the term in the pending prior application until \_\_\_\_\_
- A copy of the petition for extension of time in the **prior** application is attached.

**11. Correspondence Address:**

X Address all future communications to:

Attn: David Evans

Respectfully submitted.  
GENENTECH, INC.

Date: November 7, 2001

By: \_\_\_\_\_

David Evans  
Reg. No. \*  
Telephone No. (650) 225-1739



09157

PATENT TRADEMARK OFFICE


**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE  
UNITED STATES PATENT AND TRADEMARK OFFICE**

**LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)**

David Evans is hereby given limited recognition, *nunc pro tunc* from June 21, 2001, under 37 CFR § 10.9(b) as an employee of Genentech, Inc. to prepare and prosecute patent applications in which Genentech, Inc. is the assignee or record of the entire interest. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) David Evans ceases to lawfully reside in the United States, (ii) David Evans's employment with Genentech, Inc. ceases or is terminated, or (iii) David Evans ceases to remain or reside in the United States on an H1B visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the United States Patent and Trademark Office.

**Expires: June 21, 2002**




---

Harry I. Moatz  
Director of Enrollment and Discipline

PRO  
 U.S. PATENT AND TRADEMARK OFFICE  
 J10000 10/005306  
 11/07/01



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  Robert A. Lazarus et al.  Serial No.: 08/663,831  Filed: 14 June 1996  For: Human DNase I Hyperactive Variants	Group Art Unit: 1652  Examiner: Rao, M.
<b>CERTIFICATE OF MAILING</b> I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service addressed to the United States Patent and Trademark Office addressed to: Assistant Commissioner of Patents on	
November 7, 2001  Aida Guiam	

**PETITION AND FEE FOR TWO MONTH EXTENSION OF TIME**  
**(37 CFR 1.136(a))**

Assistant Commissioner of Patents  
 Washington, D.C. 20231

Sir:

Applicant petitions the Commissioner of Patents and Trademarks to extend the time for response to the Office Action dated May 7, 2001 for two (2) months from September 7, 2001 to November 7, 2001, in which a one month extension of time was filed on September 7, 2001. Thus, a total of three months extension is filed herewith. The extended time for response does not exceed the statutory period.

Please charge Deposit Account No. 07-0630 in the amount of \$400.00 to cover the cost of the extension. Any deficiency or overpayment should be charged or credited to this deposit account. A duplicate of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.

Date: November 7, 2001

By:   
 David Evans  
 Reg. No. \*  
 Telephone No. (650) 225-1739



09157

PATENT TRADEMARK OFFICE